Fig. 1
From: Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Exposure-response efficacy analysis of nivolumab by tumor type. Vertical lines represent 90 % prediction intervals for each dose level. CI = confidence interval; Cminss = steady-state nivolumab trough concentration; MEL = melanoma; NSCLC = non-small cell lung cancer; Obs Prob = observed probability; OR = objective response; Pred Prob = predicted probability; RCC = renal cell carcinoma